Purespring Therapeutics

📍 London, United Kingdom🗓 Founded 2020👥 55 employees💰 Last funded Nov 2024
Biotechnology Research🌐 purespringtx.com
Website LinkedIn
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Purespring Therapeutics?
Purespring Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Purespring Therapeutics last raise funding?
The most recent investment in Purespring Therapeutics recorded on gritt.io was in November 2024.
When was Purespring Therapeutics founded?
Purespring Therapeutics was founded in 2020.
What industry is Purespring Therapeutics in?
Purespring Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Purespring Therapeutics based?
Purespring Therapeutics is headquartered in London, United Kingdom.